Ganitumab
Monoclonal antibody
NY (what is this?) (verify) Ganitumab is a human monoclonal antibody against type 1 insulin-like growth factor receptor (IGF1R), designed for the treatment of cancers.[1][2]
Ganitumab was developed by Amgen. A phase III clinical trial (for metastatic pancreatic cancer) was abandoned in August 2012.[3][4]
References
- ^ "Statement On A Nonproprietary Name Adopted By The USAN Council: Ganitumab" (PDF). American MedicaAssociation.
- ^ Martínez P, Sales Fidalgo PA, Felip E (October 2014). "Ganitumab for the treatment of small-cell lung cancer". Expert Opinion on Investigational Drugs. 23 (10): 1423–32. doi:10.1517/13543784.2014.951434. PMID 25189625. S2CID 7318164.
- ^ "Amgen Pulls Cancer Drug". 10 Aug 2012. Archived from the original on 2013-07-23.
- ^ "Amgen (AMGN) Terminates Ganitumab Pancreatic Cancer Trial". 8 Aug 2012. Archived from the original on 2012-08-10.
- v
- t
- e
Monoclonal antibodies for tumors
- #WHO-EM
- ‡Withdrawn from market
- Clinical trials:
- †Phase III
- §Never to phase III
This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it. |
- v
- t
- e
This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it. |
- v
- t
- e